Gene · 23569
Papers4,322
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 4,322
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Correction: Blocking peptidyl arginine deiminase 4 confers neuroprotective effect in the post-ischemic brain through both NETosis-dependent and -independent mechanisms. | Acta Neuropathol Commun | 2025 | 40254567 | PubTator, text mining | PubMed |
| Resveratrol decreases extracellular traps (ETs) in acute promyelocytic leukemia (NB4) cells. | PLoS One | 2025 | 40245018 | PubTator, text mining | PubMed |
| Macrophage membrane-coated polydopamine nanomedicine for treating acute lung injury through modulation of neutrophil extracellular traps and M2 macrophage polarization. | Mater Today Bio | 2025 | 40225128 | PubTator, text mining | PubMed |
| Ever-Expanding Connections Between Peptidylarginine Deiminase 4 and Rheumatoid Arthritis. | Arthritis Rheumatol | 2025 | 40181788 | PubTator, text mining | PubMed |
| Anti-Peptidylarginine Deiminase 4 Autoantibodies Derived From Patients With Rheumatoid Arthritis Exert Pathogenic Effects by Activating Monocytes and Exacerbating Inflammatory Arthritis. | Arthritis Rheumatol | 2025 | 40176290 | PubTator, text mining | PubMed |
| C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer. | J Exp Clin Cancer Res | 2025 | 40148973 | PubTator, text mining | PubMed |
| A Multifaceted Computational Approach to Identify PAD4 Inhibitors for the Treatment of Rheumatoid Arthritis (RA). | Metabolites | 2025 | 40137121 | PubTator, text mining | PubMed |
| A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014-present). | Expert Opin Ther Pat | 2025 | 40136037 | PubTator, text mining | PubMed |
| Neutrophil extracellular trap-derived double-stranded RNA aggravates PANoptosis in renal ischemia reperfusion injury. | Cell Commun Signal | 2025 | 40098148 | PubTator, text mining | PubMed |
| PAD4 Inhibitor-Loaded Magnetic Fe3O4 Nanoparticles for Magnetic Targeted Chemotherapy and Magnetic Resonance Imaging of Lung Cancer. | Int J Nanomedicine | 2025 | 40093545 | PubTator, text mining | PubMed |
| Magnetizing Biotech-Advances in (In Vivo) Magnetic Enzyme Immobilization. | Eng Life Sci | 2025 | 40083857 | PubTator, text mining | PubMed |
| PADI4 facilitates stem-like properties and cisplatin resistance through upregulating PRMT2/IDs family in oesophageal squamous cell carcinoma. | Clin Transl Med | 2025 | 40078091 | PubTator, text mining | PubMed |
| Genetic Variants Associated with Suspected Neonatal Hypoxic Ischaemic Encephalopathy: A Study in a South African Context. | Int J Mol Sci | 2025 | 40076698 | PubTator, text mining | PubMed |
| Inhibition of EETosis with an anti-citrullinated histone antibody: a novel therapeutic approach for eosinophilic inflammatory disorders. | Front Immunol | 2025 | 40051617 | PubTator, text mining | PubMed |
| Ferrostatin-1 reduces the inflammatory response of rheumatoid arthritis by decreasing the antigen presenting function of fibroblast-like synoviocytes. | J Transl Med | 2025 | 40050869 | PubTator, text mining | PubMed |
| PADI4 expression in baseline circulating tumour cells acts as a prognostic biomarker in oral squamous cell carcinoma. | J Liq Biopsy | 2025 | 40027234 | PubTator, text mining | PubMed |
| Neutrophil Extracellular Traps: At the Interface of Thrombosis and Comorbidities. | Semin Thromb Hemost | 2025 | 40020757 | PubTator, text mining | PubMed |
| Neutrophils Display Novel Partners of Cytosolic Proliferating Cell Nuclear Antigen Involved in Interferon Response in COVID-19 Patients. | J Innate Immun | 2025 | 40015257 | PubTator, text mining | PubMed |
| Jinkui Shenqi decoction targets PAD4 to restrain NETosis and ameliorates psoriasis progression. | Phytomedicine | 2025 | 40010032 | PubTator, text mining | PubMed |
| Neutrophil extracellular traps license macrophage production of chemokines to facilitate CD8+ T cell infiltration in obstruction-induced renal fibrosis. | Protein Cell | 2025 | 39998389 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23569/papers?page=18